Latest Breaking News On - Oncology chief development officer - Page 9 : comparemela.com

Datopotamab deruxtecan-based combinations show promising clinical activity

Datopotamab deruxtecan-based combinations show promising clinical activity
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

Daiichi sankyoCristian massacesiOncology developmentInternational associationLung cancerPhilip levyClinical directorMedical oncologyJohns hopkins sidney kimmel cancer centerSibley memorial hospitalAssociate professorJohns hopkins university schoolChief medical officerOncology chief development officerSenior vice presidentGlobal head

Daiichi Sankyo: Datopotamab Deruxtecan-Based Combinations Show Promising Clinical Activity in Patients with Advanced Non-Small Cell Lung Cancer

Late-breaking oral presentation at WCLC features first results from TROPION-Lung02 trial of Daiichi Sankyo and AstraZeneca's TROP2 directed antibody drug conjugate Initial results from the TROPION-Lung02

United statesJapan generalMasashi kawaseAnn oncDaiichi sankyoRose talaricoCristian massacesiDaiichi sankyo companyNational cancer instituteMerck co incInternational agency for research on cancerVirtual congressAmerican cancer societyCenters for diseaseDaiichi sankyo incOncology development

Datopotamab Deruxtecan-Based Combinations Show Promising Clinical Activity in Patients with Advanced Non-Small Cell Lung Cancer

TOKYO & BASKING RIDGE, N.J. (BUSINESS WIRE) Aug 9, 2022

United statesJapan generalMasashi kawaseAnn oncDaiichi sankyoRose talaricoCristian massacesiDaiichi sankyo companyNational cancer instituteMerck co incInternational agency for research on cancerVirtual congressAmerican cancer societyCenters for diseaseDaiichi sankyo incOncology development

Investegate |Hutchmed China Ltd Announcements | Hutchmed China Ltd: Preliminary results from SAVANNAH Phase 2 Trial

Investegate announcements from Hutchmed China Ltd, Preliminary results from SAVANNAH Phase 2 Trial

Hong kongSoult ukpyolsiSouth koreaUnited statesUnited kingdomMyung ju ahnAtholl tweedie freddy crossleyDaiichi sankyoAsia zhou yiWeiguo suCristian massacesiMark leeAnnie chengSungkyunkwan university school of medicineChina limitedCompany on twitter astrazeneca

HUTCHMED and AstraZeneca Announce that

MET is the most common biomarker in patients with EGFR-mutated lung cancer who develop resistance to targeted therapy Global SAFFRON Phase.

Soult ukpyolsiSouth koreaUnited statesMyung ju ahnCristian massacesiWeiguo suChina limitedSamsung medical centerSungkyunkwan university school of medicineDepartment of medicineInternational associationLung cancerSungkyunkwan university schoolPrincipal investigatorChief medical officerOncology chief development officer